{"id":35499,"date":"2020-12-21T15:41:31","date_gmt":"2020-12-21T15:41:31","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=35499"},"modified":"2021-03-18T09:37:27","modified_gmt":"2021-03-18T09:37:27","slug":"nicolas-camper","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/nicolas-camper\/","title":{"rendered":"Nicolas Camper"},"content":{"rendered":"<div class=\"vgblk-rw-wrapper limit-wrapper\">\n<h2>Nicolas Camper<\/h2>\n<h4>Group Leader, Bioconjugation Chemistry at Abzena<\/h4>\n\t<p>Dr. Nicolas Camper is Group Leader for Bioconjugation Chemistry at Abzena. His group focuses on the design and synthesis of antibody-drug conjugates with different combinations of conjugation technologies, linker designs and payloads for pre-clinical evaluation, helping Abzena&#8217;s clients establish Proof of Concept and select Lead Candidates for further development. Prior to his position at Abzena, Nicolas worked for PolyTherics where he was involved in the development of the ThioBridge\u00ae disulfide rebridging conjugation technology from the early stage. At PolyTherics, Nicolas led CMC efforts resulting in the manufacturing of the first ThioBridge\u00ae ADC.<\/p>\n<p>He holds a PhD from Queen&#8217;s University of Belfast, on the synthesis of bisphosphonate conjugates to antibody fragments for applications in oncology. Nicolas has experience in bioconjugation, protein engineering, protein expression in bacterial and mammalian systems as well as synthetic chemistry.<\/p>\n\t\t\t\t\t\t\t<img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Nicolas_Camper_abzena_biotech_Pharma_Summit_2021_gallery.jpg\" alt=\"Nicolas_Camper_abzena_biotech_Pharma_Summit_2021_gallery\" itemprop=\"image\" height=\"1224\" width=\"820\" title=\"Nicolas_Camper_abzena_biotech_Pharma_Summit_2021_gallery\" onerror=\"this.style.display='none'\" sizes=\"(max-width: 768px) 100vw, 100vw\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Nicolas_Camper_abzena_biotech_Pharma_Summit_2021_gallery.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Nicolas_Camper_abzena_biotech_Pharma_Summit_2021_gallery-201&#215;300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Nicolas_Camper_abzena_biotech_Pharma_Summit_2021_gallery-686&#215;1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Nicolas_Camper_abzena_biotech_Pharma_Summit_2021_gallery-768&#215;1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Nicolas_Camper_abzena_biotech_Pharma_Summit_2021_gallery-630&#215;940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Nicolas_Camper_abzena_biotech_Pharma_Summit_2021_gallery-420&#215;627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Nicolas_Camper_abzena_biotech_Pharma_Summit_2021_gallery-315&#215;470.jpg 315w&#8221;>\t\t\t\t\t\t\t\n<h3>\n\tTitle: Designing and Developing Next-Generation Antibody-Drug Conjugate Medicines\n\t<\/h3>\n\t<div class=\"su-expand su-expand-collapsed su-expand-link-style-default\" data-height=\"200\"><div class=\"su-expand-content su-u-trim\" style=\"color:#333333;max-height:200px;overflow:hidden\">\n<ul>\n<li>Deep industry knowledge can be leveraged to support target product profiling for the development of next-generation Antibody-Drug Conjugates (ADCs).<\/li>\n<li>Design and developability assessments help select successful next-generation ADCs by identifying the right delivery antibody, linker and payload combination using an integrated approach across a multidisciplinary team.<\/li>\n<li>Process development and GMP manufacturing capabilities of the highly potent payload, the linker, the antibody and the ADC, reduce the overall time to clinic by integrating multiple work streams to accelerate next-generation ADC production for IND submission<\/li>\n<\/ul>\n<\/div><div class=\"su-expand-link su-expand-link-more\" style=\"text-align:left\"><a href=\"javascript:;\" style=\"color:#0088FF;border-color:#0088FF\"><span style=\"border-color:#0088FF\">Show more<\/span><\/a><\/div><div class=\"su-expand-link su-expand-link-less\" style=\"text-align:left\"><a href=\"javascript:;\" style=\"color:#0088FF;border-color:#0088FF\"><span style=\"border-color:#0088FF\">Show less<\/span><\/a><\/div><\/div>\n<h4>\n\t\t\t<a href=\"#\" title=\"On the Web\" target=\"_self\" rel=\"noopener\">\n\tOn the Web\n\t\t\t<\/a>\n\t<\/h4>\n\t\n<h4>\n\t\t\t<a href=\"#\" title=\"On LinkedIn\" target=\"_self\" rel=\"noopener\">\n\tOn LinkedIn\n\t\t\t<\/a>\n\t<\/h4>\n<\/div><!-- .vgblk-rw-wrapper -->","protected":false},"excerpt":{"rendered":"<p>Nicolas Camper Group Leader, Bioconjugation Chemistry at Abzena Dr. Nicolas Camper is Group Leader for Bioconjugation Chemistry at Abzena. His group focuses on the design and synthesis of antibody-drug conjugates with different combinations of conjugation technologies, linker designs and payloads for pre-clinical evaluation, helping Abzena&#8217;s clients establish Proof of Concept and select Lead Candidates for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":35500,"parent":34722,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-35499","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Nicolas Camper &#8226; BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"Dr. Nicolas Camper is Group Leader for Bioconjugation Chemistry at Abzena. His group focuses on the design and synthesis of antibody-drug conjugates with different combinations of conjugation technologies\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/nicolas-camper\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicolas Camper &#8226; BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"Dr. Nicolas Camper is Group Leader for Bioconjugation Chemistry at Abzena. His group focuses on the design and synthesis of antibody-drug conjugates with different combinations of conjugation technologies\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/nicolas-camper\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-18T09:37:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Nicolas_Camper_abzena_biotech_Pharma_Summit_2021_profile.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/nicolas-camper\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/nicolas-camper\/\",\"name\":\"Nicolas Camper &#8226; BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/nicolas-camper\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/nicolas-camper\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Nicolas_Camper_abzena_biotech_Pharma_Summit_2021_profile.jpg\",\"datePublished\":\"2020-12-21T15:41:31+00:00\",\"dateModified\":\"2021-03-18T09:37:27+00:00\",\"description\":\"Dr. Nicolas Camper is Group Leader for Bioconjugation Chemistry at Abzena. His group focuses on the design and synthesis of antibody-drug conjugates with different combinations of conjugation technologies\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/nicolas-camper\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/nicolas-camper\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/nicolas-camper\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Nicolas_Camper_abzena_biotech_Pharma_Summit_2021_profile.jpg\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Nicolas_Camper_abzena_biotech_Pharma_Summit_2021_profile.jpg\",\"width\":900,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/nicolas-camper\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antibody Engineering &#038; Therapeutics 2021 Speakers\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nicolas Camper\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow&#039;s healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicolas Camper &#8226; BioTech Pharma Summit","description":"Dr. Nicolas Camper is Group Leader for Bioconjugation Chemistry at Abzena. His group focuses on the design and synthesis of antibody-drug conjugates with different combinations of conjugation technologies","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/nicolas-camper\/","og_locale":"en_US","og_type":"article","og_title":"Nicolas Camper &#8226; BioTech Pharma Summit","og_description":"Dr. Nicolas Camper is Group Leader for Bioconjugation Chemistry at Abzena. His group focuses on the design and synthesis of antibody-drug conjugates with different combinations of conjugation technologies","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/nicolas-camper\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2021-03-18T09:37:27+00:00","og_image":[{"width":900,"height":900,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Nicolas_Camper_abzena_biotech_Pharma_Summit_2021_profile.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/nicolas-camper\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/nicolas-camper\/","name":"Nicolas Camper &#8226; BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/nicolas-camper\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/nicolas-camper\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Nicolas_Camper_abzena_biotech_Pharma_Summit_2021_profile.jpg","datePublished":"2020-12-21T15:41:31+00:00","dateModified":"2021-03-18T09:37:27+00:00","description":"Dr. Nicolas Camper is Group Leader for Bioconjugation Chemistry at Abzena. His group focuses on the design and synthesis of antibody-drug conjugates with different combinations of conjugation technologies","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/nicolas-camper\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/nicolas-camper\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/nicolas-camper\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Nicolas_Camper_abzena_biotech_Pharma_Summit_2021_profile.jpg","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Nicolas_Camper_abzena_biotech_Pharma_Summit_2021_profile.jpg","width":900,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/nicolas-camper\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Antibody Engineering &#038; Therapeutics 2021 Speakers","item":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/"},{"@type":"ListItem","position":3,"name":"Nicolas Camper"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow&#039;s healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/35499","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=35499"}],"version-history":[{"count":4,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/35499\/revisions"}],"predecessor-version":[{"id":35910,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/35499\/revisions\/35910"}],"up":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/34722"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/35500"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=35499"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}